Phase III multinational, randomized, double-blind, placebo-controlled study of tivantinib (ARQ 197) plus erlotinib versus erlotinib alone in previously treated patients with locally advanced or metastatic nonsquamous non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 33, Issue 24, 2015, Pages 2667-2674

  Scagliotti, Giorgio ^a   Von Pawel, Joachim ^d   Novello, Silvia ^a   Ramlau, Rodryg ^e   Favaretto, Adolfo ^b   Barlesi, Fabrice ^f   Akerley, Wallace ^g   Orlov, Sergey ^h   Santoro, Armando ^c   Spigel, David ⁱ   Hirsh, Vera ^j   Shepherd, Frances A ^k   Sequist, Lecia V ^l   Sandler, Alan ^o   Ross, Jeffrey S ^m   Wang, Qiang ^p   Von Roemeling, Reinhard ^p   Shuster, Dale ^p   Schwartz, Brian ⁿ  

^a UNIVERSITY OF TURIN   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^c HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^d ASKLEPIOS FACHKLINIKEN MÜNCHEN GAUTING   (Germany)

^e POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^f AIX MARSEILLE UNIVERSITY   (France)

^g UNIVERSITY OF UTAH   (United States)

^h PAVLOV FIRST SAINT PETERSBURG STATE MEDICAL UNIVERSITY   (Russian Federation)

ⁱ Clinical Locations   (United States)

^j MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^k PRINCESS MARGARET HOSPITAL   (Canada)

^l MASSACHUSETTS GENERAL HOSPITAL   (United States)

^m FOUNDATION MEDICINE   (United States)

ⁿ ARQULE INC   (United States)

^o GENENTECH INC   (United States)

^p DAIICHI SANKYO INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; K RAS PROTEIN; PLACEBO; TIVANTINIB; 2 PYRROLIDONE DERIVATIVE; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE; QUINOLINE DERIVATIVE;

ADULT; ADVANCED CANCER; ARTICLE; ASTHENIA; BONE MARROW SUPPRESSION; BRADYCARDIA; BRONCHOPNEUMONIA; CANCER COMBINATION CHEMOTHERAPY; CANCER FATIGUE; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DERMATITIS; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG WITHDRAWAL; DYSPNEA; FEBRILE NEUTROPENIA; FEMALE; GENE AMPLIFICATION; HUMAN; INTERSTITIAL LUNG DISEASE; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPENIA; NEUTROPHIL COUNT; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PATIENT SAFETY; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; SEPSIS; SEPTIC SHOCK; SIDE EFFECT; THROMBOCYTE COUNT; TREATMENT OUTCOME; TREATMENT RESPONSE; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; LUNG NEOPLASMS; MIDDLE AGED; PATHOLOGY; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PYRROLIDINONES; QUINAZOLINES; QUINOLINES; YOUNG ADULT;

EID: 84940394869     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.60.7317     Document Type: Article

References (36)

1. World Health Organization: GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. Lyon, France, International Agency for Research on Cancer, 2012
2. American Cancer Society: Cancer Facts & Figures 2012. Atlanta, GA, American Cancer Society, 2012
3. NSCLC Meta-Analyses Collaborative Group: Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: A systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 26:4617-4625, 2008
4. Feng Y, Ma PC: MET targeted therapy for lung cancer: Clinical development and future directions. Lung Cancer (Auckl) 3:53-67, 2012
5. Peters S, Adjei AA: MET: A promising anticancer therapeutic target. Nat Rev Clin Oncol 9:314-326, 2012
6. Scagliotti GV, Novello S, von Pawel J: The emerging role of MET/HGF inhibitors in oncology. Cancer Treat Rev 39:793-801, 2013
7. Eathiraj S, Palma R, Volckova E, et al: Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-MET) protein autophosphorylation by ARQ 197. J Biol Chem 286:20666-20676, 2011
8. Munshi N, Jeay S, Li Y, et al: ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol Cancer Ther 9:1544-1553, 2010
9. Ludovini V, Bianconi F, Pistola L, et al: Optimization of patient selection for EGFR- TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations. Cancer Chemother Pharmacol 69:1289-1299, 2012
10. Cappuzzo F, Ciuleanu T, Stelmakh L, et al: Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: A multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 11:521-529, 2010
11. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132, 2005
12. Sequist LV, von Pawel J, Garmey EG, et al: Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol 29:3307-3315, 2011
13. Scagliotti GV, Novello S, Schiller JH, et al: Rationale and design of MARQUEE: A phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer. Clin Lung Cancer 13:391-395, 2012
14. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247, 2009
15. Lan KKG, DeMets DL: Discrete sequential boundaries for clinical trials. Biometrika 70:659-663, 1983
16. Azuma K, Yoshioka H, Yamamoto N, et al: Tivantinib plus erlotinib versus placebo plus erlotinib in Asian patients with previously treated nonsquamous NSCLC with wild-type EGFR: First report of a phase III ATTENTION trial. J Clin Oncol 32:516s, 2014 (suppl 15s; abstr 8044)
17. Tarceva (erlotinib): Prescribing information. San Francisco, CA, Genentech, 2014
18. Cui JJ: Targeting receptor tyrosine kinase MET in cancer: Small molecule inhibitors and clinical progress. J Med Chem 57:4427-4453, 2014
19. Eng C, Bendell J, Bessudo A, et al: Phase I results of the randomized, placebo controlled, phase I/II study of the novel oral c-Met inhibitor, ARQ 197, irinotecan (CPT-11), and cetuximab (C) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC) who have received front-line systemic therapy. J Clin Oncol 29:241s, 2011 (suppl; abstr 3582)
20. Goldman JW, Laux I, Chai F, et al: Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib. Cancer 118:5903-5911, 2012
21. Kang YK, Muro K, Ryu MH, et al: A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer. Invest New Drugs 32:355-361, 2014
22. Rimassa L, Personeni N, Simonelli M, et al: Tivantinib: A new promising mesenchymal-epithelial transition factor inhibitor in the treatment of hepatocellular carcinoma. Future Oncol 9:153-165, 2013
23. Santoro A, Rimassa L, Borbath I, et al: Tivantinib for second-line treatment of advanced hepatocellular carcinoma: A randomised, placebo-controlled phase 2 study. Lancet Oncol 14:55-63, 2013
24. Yamamoto N, Murakami H, Hayashi H, et al: CYP2C19 genotype-based phase I studies of a c-Met inhibitor tivantinib in combination with erlotinib, in advanced/metastatic non-small cell lung cancer. Br J Cancer 109:2803-2809, 2013
25. Basilico C, Pennacchietti S, Vigna E, et al: Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET. Clin Cancer Res 19:2381-2392, 2013
26. Calles A, Kwiatkowski N, Cammarata BK, et al: Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non-small-cell lung cancer cell lines. Mol Oncol, 9:260-269, 2015
27. Katayama R, Aoyama A, Yamori T, et al: Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition. Cancer Res 73:3087-3096, 2013
28. Remsing Rix LL, Kuenzi BM, Luo Y, et al: GSK3 alpha and beta are new functionally relevant targets of tivantinib in lung cancer cells. ACS Chem Biol 9:353-358, 2014
29. Kanteti R, Dhanasingh I, Kawada I, et al: MET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma. PLoS One 9:e105919, 2014
30. Xalkori (crizotinib): Prescribing information. New York, NY, Pfizer, 2014
31. Forde PM, Rudin CM: Crizotinib in the treatment of non-small-cell lung cancer. Expert Opin Pharmacother 13:1195-1201, 2012
32. Shaw AT, Kim DW, Nakagawa K, et al: Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368:2385-2394, 2013
33. Camidge DR, Bang YJ, Kwak EL, et al: Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: Updated results from a phase 1 study. Lancet Oncol 13:1011-1019, 2012
34. Camidge DR, Ou SI, Shapiro GI, et al: Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC). J Clin Oncol 32:506s, 2014 (suppl 15s; abstr 8001)
35. Spigel DR, Ervin TJ, Ramlau RA, et al: Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol 31:4105-4114, 2013
36. Spigel DR, Edelman M, O'Byrne K, et al: Onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIb or IV NSCLC: Results from the pivotal phase III randomized, multicenter, placebo-controlled METLung (OAM4971g) global trial. J Clin Oncol 32:506s, 2014 (suppl 15s; abstr 8000)